Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16).
Mollee P, Reynolds J, Janowski W, Quach H, Campbell P, Gibbs S, Lee S, Lee E, Taylor K, Cochrane T, Wallington-Gates C, Kwok F, Weber N, Kerridge I, Weston H, Ho PJ, Leahy MF, Horvath N, Spencer A.
Mollee P, et al. Among authors: spencer a.
Blood Adv. 2024 May 13:bloodadvances.2023012539. doi: 10.1182/bloodadvances.2023012539. Online ahead of print.
Blood Adv. 2024.
PMID: 38739707